Marinus Pharmaceuticals (MRNS) Forms $7.07 Double Top; Navigant Consulting (NCI) Sentiment Is 1.12

November 14, 2017 - By Migdalia James

Navigant Consulting, Inc. is a global professional services company. The company has market cap of $811.41 million. The Firm serves clients in the healthcare, energy and financial services industries. It has a 18.9 P/E ratio. It operates through four divisions.

Marinus Pharmaceuticals Inc (MRNS) formed double top with $7.64 target or 8.00% above today’s $7.07 share price. Marinus Pharmaceuticals Inc (MRNS) has $285.84M valuation. About 173,495 shares traded. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 74.89% since November 14, 2016 and is downtrending. It has underperformed by 91.59% the S&P500.

About 3,300 shares traded. Navigant Consulting, Inc. (NCI) has risen 27.76% since November 14, 2016 and is uptrending. It has outperformed by 11.06% the S&P500.

Analysts await Navigant Consulting, Inc. (NYSE:NCI) to report earnings on February, 15. They expect $0.40 earnings per share, up 33.33% or $0.10 from last year’s $0.3 per share. NCI’s profit will be $18.37 million for 11.04 P/E if the $0.40 EPS becomes a reality. After $0.30 actual earnings per share reported by Navigant Consulting, Inc. for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Tieton Capital Management Llc holds 1.71% of its portfolio in Navigant Consulting, Inc. for 93,584 shares. Tributary Capital Management Llc owns 876,423 shares or 1.53% of their US portfolio. Moreover, Dalton Greiner Hartman Maher & Co has 0.9% invested in the company for 784,881 shares. The Florida-based Independent Portfolio Consultants Inc. has invested 0.36% in the stock. Northwest Investment Counselors Llc, a Oregon-based fund reported 40,402 shares.

Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was initiated by Jefferies with “Buy” on Tuesday, November 17. The firm has “Buy” rating by Jefferies given on Tuesday, June 14. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, December 17. The firm earned “Buy” rating on Tuesday, March 8 by Stifel Nicolaus. The rating was maintained by Oppenheimer with “Outperform” on Friday, October 30. The rating was maintained by Jefferies with “Buy” on Wednesday, August 10. Oppenheimer downgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) on Tuesday, June 14 to “Perform” rating. The firm earned “Sector Perform” rating on Tuesday, June 14 by RBC Capital Markets. On Wednesday, August 5 the stock rating was maintained by Oppenheimer with “Outperform”.

Investors sentiment decreased to 0.54 in 2017 Q2. Its down 2.06, from 2.6 in 2017Q1. It turned negative, as 6 investors sold Marinus Pharmaceuticals Inc shares while 7 reduced holdings. 4 funds opened positions while 3 raised stakes. 6.99 million shares or 7.29% more from 6.52 million shares in 2017Q1 were reported. Royal Financial Bank Of Canada owns 4 shares for 0% of their portfolio. Geode Mngmt Ltd Liability holds 0% or 54,158 shares. Creative Planning holds 0% or 500 shares. Panagora Asset Mgmt Incorporated stated it has 3,573 shares or 0% of all its holdings. Northern Corp holds 0% or 21,470 shares. Vanguard Group Incorporated Incorporated invested in 583,654 shares or 0% of the stock. Boothbay Fund Management Ltd Liability Com invested in 31,464 shares or 0.01% of the stock. Moreover, Deutsche Bank & Trust Ag has 0% invested in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Jennison Limited Liability reported 811,665 shares. Acadian Asset Ltd Liability holds 4,326 shares or 0% of its portfolio. Granite Point Mngmt Lp accumulated 0.26% or 766,448 shares. Tower Rech Capital Llc (Trc) invested in 0% or 5,201 shares. J Goldman And Co L P invested in 0.03% or 389,288 shares. Sphera Funds Mgmt owns 0.31% invested in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 1.33 million shares. Orbimed Advsrs Limited Liability invested in 567,600 shares or 0.01% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.